Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CStone Pharmaceuticals ( (HK:2616) ) has provided an update.
CStone Pharmaceuticals announced the enrollment of the first patient in Australia for their global Phase II clinical trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody. This trial, which will expand to the United States, aims to evaluate the drug’s safety, tolerability, and efficacy across multiple tumor types, including lung, liver, colorectal, ovarian, breast, and cervical cancers. The Phase I study showed promising results with favorable safety and significant antitumor activity, suggesting potential advancements in treatment options for various cancers.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative immuno-oncology therapies. The company is known for its research and development of targeted therapies and immunotherapies, particularly in the oncology sector, with a market focus on global clinical trials and drug development.
Average Trading Volume: 22,971,684
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.28B
See more data about 2616 stock on TipRanks’ Stock Analysis page.